INT236621

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.53
First Reported 2008
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 7
Total Number 8
Disease Relevance 6.16
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (KRAS) mitochondrion (KRAS) plasma membrane (KRAS)
GTPase activity (KRAS)
Anatomy Link Frequency
arm 1
body 1
KRAS (Homo sapiens)
Pain Link Frequency Relevance Heat
fibrosis 9 5.00 Very Low Very Low Very Low
pruritus 5 5.00 Very Low Very Low Very Low
palliative 4 5.00 Very Low Very Low Very Low
Inflammation 4 5.00 Very Low Very Low Very Low
abdominal pain 4 5.00 Very Low Very Low Very Low
pain pelvic 2 5.00 Very Low Very Low Very Low
cva 2 5.00 Very Low Very Low Very Low
antagonist 2 5.00 Very Low Very Low Very Low
Pain 2 5.00 Very Low Very Low Very Low
backache 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Endometrial Cancer 306 100.00 Very High Very High Very High
Hepatitis C Virus Infection 115 99.98 Very High Very High Very High
Acquired Immune Deficiency Syndrome Or Hiv Infection 12 99.24 Very High Very High Very High
Microsatellite Instability 98 99.08 Very High Very High Very High
Toxicity 49 98.20 Very High Very High Very High
Cancer 290 97.56 Very High Very High Very High
Aneuploidy 6 96.32 Very High Very High Very High
Chromosomal Instability 2 92.08 High High
Colorectal Cancer 74 91.24 High High
Carcinoma 124 80.96 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Additionally, a third report has shown that mutations affecting either KRAS or BRAF are predictive and prognostic indicators in mCRC patients, and are inversely correlated with response to anti-EGFR monoclonal antibodies [16].
Regulation (affecting) of KRAS
1) Confidence 0.53 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2432064 Disease Relevance 0.36 Pain Relevance 0
Moreover, pooling all published studies evaluating this putative association further suggests that KRAS mutations strongly negatively affect the probability of objective response to cetuximab treatment.
Regulation (affect) of KRAS
2) Confidence 0.44 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2432064 Disease Relevance 0.61 Pain Relevance 0
KRAS mutation status, on the other hand, is not in itself a prognostic marker.67,68
Neg (not) Regulation (is) of KRAS
3) Confidence 0.36 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886318 Disease Relevance 0.37 Pain Relevance 0
Amado et al evaluated KRAS mutational status on patients treated in a randomized, trial evaluating panitumumab vs best supportive care.60 KRAS mutational status was obtained on 427 (92%) of 463 patients (208 panitumumab arm, 219 BSC).
Regulation (evaluated) of KRAS in arm
4) Confidence 0.36 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886332 Disease Relevance 0.58 Pain Relevance 0
The same effect of KRAS mutational status has also been reported with cetuximab therapy.56,61 On the basis of these results, the European Union drug regulatory body, the European Medicines Agency, has approved panitumumab only for metastatic CRC patients whose tumors display only wild-type KRAS (Table 3).
Regulation (effect) of KRAS in body associated with colorectal cancer and cancer
5) Confidence 0.36 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886332 Disease Relevance 0.46 Pain Relevance 0
Only two direct-acting HCV inhibitors entered phase III trials in 2008, both of which are PIs (telaprevir and boceprevir).31 The success of HIV antiviral therapy gave hope that HCV NS3-4A protease could be an excellent target for a structural-base design approach.
Regulation (target) of NS3 associated with acquired immune deficiency syndrome or hiv infection and hepatitis c virus infection
6) Confidence 0.26 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2731021 Disease Relevance 0.92 Pain Relevance 0
Furthermore, none of the five main alterations of endometrioid endometrial carcinoma (mutations of PTEN, PIK3CA, KRAS, and CTNNB1 genes and MSI) plays a major role in non-endometrioid endometrial carcinoma.
Regulation (alterations) of KRAS associated with microsatellite instability and endometrial cancer
7) Confidence 0.22 Published 2010 Journal Obstetrics and Gynecology International Section Body Doc Link PMC2846683 Disease Relevance 1.56 Pain Relevance 0
They are associated with a number of well-described genetic alterations including mutations of PTEN, KRAS, ?
Regulation (alterations) of KRAS
8) Confidence 0.22 Published 2010 Journal Obstetrics and Gynecology International Section Body Doc Link PMC2846683 Disease Relevance 1.29 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox